MEDICAL PROPERTIES TRUST INC 8-K

What Happened

• Medical Properties Trust, Inc. (MPT) filed an 8-K on June 1, 2026 reporting the results of its annual meeting of stockholders held May 28, 2026 (record date March 19, 2026). A quorum was present with 468,686,557 of 602,829,003 outstanding shares represented.
• All nine director nominees were elected. Vote totals (for/against/abstain) ranged from 319.3M–329.9M for each nominee, with 122,390,383 broker non‑votes recorded for the director elections.
• PricewaterhouseCoopers LLP was ratified as MPT’s independent registered public accounting firm for 2026 (459,883,831 for; 6,189,396 against; 2,613,330 abstain).
• Stockholder advisory vote on named executive officer (NEO) compensation (say-on-pay) passed (245,721,749 for; 96,721,390 against; 3,853,035 abstain). The company’s Second Amended and Restated 2019 Equity Incentive Plan was approved (280,147,111 for; 60,763,845 against; 5,385,218 abstain).

Key Details

• Record date: March 19, 2026; Meeting date: May 28, 2026; Form 8‑K filed June 1, 2026.
• Shares outstanding entitled to vote: 602,829,003; shares represented at meeting: 468,686,557; broker non‑votes: 122,390,383 (~20.3% of outstanding shares).
• Director election support: each nominee received roughly 92–94% of the votes cast on director elections (for example, Caterina A. Mozingo: 329,917,176 for).
• Auditor ratification: PwC ratified with ~98.2% of votes cast in favor. Say-on-pay received ~71.0% of votes cast in favor; Equity Incentive Plan received ~80.9% of votes cast in favor.

Why It Matters

• Board continuity: Re-election of all nine directors maintains existing governance and leadership continuity for investors to consider when evaluating strategy and oversight.
• Audit stability: Ratification of PwC provides continuity for financial reporting and audit oversight for fiscal 2026.
• Pay and compensation signals: The advisory say‑on‑pay passed but with notable opposition (~29% of votes cast against), which investors may monitor as a governance and compensation concern. Approval of the amended equity incentive plan authorizes additional equity awards under the plan, which can affect future dilution and executive pay — investors should review the proxy for plan specifics.